Organon & Co. (NYSE:OGN) Shares Acquired by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC increased its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 42.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 247,491 shares of the company's stock after purchasing an additional 74,242 shares during the quarter. U.S. Capital Wealth Advisors LLC owned approximately 0.10% of Organon & Co. worth $3,569,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in OGN. New York State Teachers Retirement System increased its holdings in Organon & Co. by 20.1% during the fourth quarter. New York State Teachers Retirement System now owns 348,226 shares of the company's stock worth $5,021,000 after buying an additional 58,321 shares during the last quarter. State of Alaska Department of Revenue increased its position in Organon & Co. by 417.8% in the fourth quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company's stock worth $2,267,000 after buying an additional 126,882 shares during the last quarter. KLCM Advisors Inc. lifted its position in shares of Organon & Co. by 60.4% during the 4th quarter. KLCM Advisors Inc. now owns 999,099 shares of the company's stock valued at $14,407,000 after buying an additional 376,055 shares during the last quarter. State of New Jersey Common Pension Fund D grew its stake in shares of Organon & Co. by 59.1% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 221,461 shares of the company's stock worth $3,193,000 after acquiring an additional 82,239 shares during the period. Finally, UBS Group AG raised its stake in Organon & Co. by 88.3% in the 3rd quarter. UBS Group AG now owns 657,912 shares of the company's stock valued at $11,421,000 after acquiring an additional 308,470 shares during the period. 77.43% of the stock is owned by institutional investors.

Insider Transactions at Organon & Co.

In related news, insider Kirke Weaver acquired 2,720 shares of the company's stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $18.36 per share, with a total value of $49,939.20. Following the acquisition, the insider now owns 15,181 shares of the company's stock, valued at approximately $278,723.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.17% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on OGN. The Goldman Sachs Group upped their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the company a "neutral" rating in a research note on Friday. Piper Sandler lifted their price target on Organon & Co. from $22.00 to $24.00 and gave the company an "overweight" rating in a research report on Monday, April 29th.

Organon & Co. Trading Up 0.6 %

Shares of Organon & Co. stock traded up $0.11 during trading on Friday, hitting $19.61. The stock had a trading volume of 3,217,591 shares, compared to its average volume of 2,337,626. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $24.08. The firm has a market cap of $5.04 billion, a price-to-earnings ratio of 4.79, a P/E/G ratio of 0.92 and a beta of 0.81. The business's 50-day moving average is $18.19 and its 200 day moving average is $15.77.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.73 by $0.14. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a negative return on equity of 259.73% and a net margin of 16.50%. As a group, equities analysts expect that Organon & Co. will post 4.1 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Shareholders of record on Monday, May 13th will be paid a $0.28 dividend. The ex-dividend date of this dividend is Friday, May 10th. This represents a $1.12 dividend on an annualized basis and a yield of 5.71%. Organon & Co.'s dividend payout ratio is presently 27.38%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.